|Bid||7.61 x 110000|
|Ask||7.64 x 110000|
|Day's Range||7.22 - 7.22|
|52 Week Range||5.53 - 21.32|
|Beta (3Y Monthly)||2.30|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
On a per-share basis, the Henderson, Nevada-based company said it had a loss of 17 cents. Losses, adjusted for one-time gains and costs, were 27 cents per share. Spectrum Pharma shares have climbed slightly ...
popped Thursday after the company announced that it was selling its marketed portfolio of seven Food and Drug Administration-approved products to Acrotech Biopharma for $160 million up front, with a potential for another $140 million in regulatory and sales-based milestones. The company will reduce its staff size by about 40% as a result of the deal, with the impacted staff transitioning over to Acrotech. "This divestiture marks a major strategic shift for Spectrum to ensure laser-focus on novel, oncology drug development and commercialization," said Joe Turgeon, president and CEO of Spectrum Pharmaceuticals.
The biopharma announced that one of its drug candidates is closer to hitting the market, but investors aren't in a celebratory mood.
Spectrum Pharma announced Wednesday after the close that the FDA declined to accord Breakthrough Therapy Designation, or BTD, for poziotinib, its pipeline candidate that is being evaluated in the ZENITH20 study in patients with metastatic non-small cell lung cancer and EGFR exon 20 tumor mutations. Now that the BTD designation is being denied, the existing development plan and timeline for a NDA filing based on the first cohort of the ZENITH20 trial still holds, the company said.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 19) Endocyte, Inc. (NASDAQ: ECYT ) Down In The Dumps (Biotech ...
Tilray TLRY shares surged as much as 19 percent after hours after the company announced it entered into a $100 million joint venture with AB InBev. The beer brewer and Tilray will study non-alcoholic cannabis-based beverages in Canada. The joint venture, in which both companies will invest $50 million each, will study non-alcoholic beverages containing THC, the intoxicating chemical compound in marijuana, as well as CBD, the non-psychoactive compound.
The company announced third-quarter 2018 earnings and a pipeline update, but investors weren't happy with results from an important trial announced in early December.
Spectrum (SPPI) reports narrower-than-expected loss in the third quarter and also beats on revenues. The company is on track to file a BLA for Rolontis by year end.
Spectrum Pharma (SPPI) delivered earnings and revenue surprises of 22.73% and 2.72%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Henderson, Nevada-based company said it had a loss of 66 cents per share. Losses, adjusted for non-recurring costs, were 17 cents per share. The biotechnology company posted revenue of $25.3 million ...
Spectrum Pharma (SPPI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 18) Endocyte, Inc. (NASDAQ: ECYT )( announced a deal to ...
Spectrum Pharmaceuticals (SPPI) needs investors to pay close attention to the stock based on moves in the options market lately.
Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Spectrum Pharmaceuticals Inc (NASDAQ:SPPI) with a market-capitalization of US$2.22b, rarely draw their attention. While they are lessRead More...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Sept. 5) Aptinyx Inc (NASDAQ: APTX ) Avanos Medical Inc (NYSE: AVNS ...
Investors in Spectrum Pharmaceuticals (SPPI) need to pay close attention to the stock based on moves in the options market lately.
Spectrum (SPPI) reports wider-than-expected loss in the second quarter and misses on revenues. Rolontis successful in second phase III study.
Spectrum Pharma (SPPI) delivered earnings and revenue surprises of -16.67% and -13.79%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?